PRISM Mid-Day Movers: Cybersecurity and Healthcare are Today’s Leaders. BIO-key International (NASDAQ: $BKYI ) shares rose roughly 28% to $2.6950, gaining $0.5950 per share, by midday. Lucid Diagnostics (NASDAQ: $LUCD ) shares rose almost 26% to $0.3858, gaining $0.0581 per share. The advance followed news that the company began receiving Medicare reimbursement for its EsoGuard test and closed a $15 million financing. Other Notable Movers: Quantum-Si Inc. ($QSI) up 13% CalciMedica ($CALC) up 11% SHF Holdings, Inc. ($SHFS ) down -48% Stock prices and percentage changes are as of 12:00 p.m. ET on October 23, 2026, and are subject to change. prismmarketview.com/prism-mi…

$BLRX BioLineRx and Hemispherian presented preclinical data at ESMO 2026 suggesting GLIX1 can extend the activity of PARP inhibitors in HR-proficient ovarian cancer, tumors that tend to be less sensitive to these drugs. → Lab: GLIX1 enhanced olaparib, veliparib, and niraparib across several HR-proficient cell lines (ZIP synergy scores 10.9 to 43.2) → 28-day mouse study using patient-derived tumor tissue: low-dose GLIX1 plus olaparib significantly slowed tumor growth vs. vehicle, with growth inhibition comparable to cisplatin in that model → BioLineRx plans to add an ovarian cancer arm during the expansion phase of its ongoing GLIX1 trial (no start date given) prismmarketview.com/bioliner…

Evaxion ($EVAX) reported three-year phase 2 data for EVX-01, its personalized cancer vaccine in advanced melanoma: 89% of the vaccine's targets generated tumor-specific T-cell responses, up from 86% at two years. Each patient gets a vaccine designed from their own tumor. Six of the 12 responders kept taking EVX-01 alone for a third year, and all maintained their response with no tumor progression. The trial enrolled 16 patients. The data goes to ESMO on Oct. 24. prismmarketview.com/evaxion-…

$CRLBF Cresco Labs opened Sunnyside Prestonsburg in Kentucky, the company’s 83rd dispensary nationwide. → Per the company, dispensaries are now operating in all 11 regions of Kentucky’s medical cannabis program for the first time → Medical program only, in Eastern Kentucky; CEO Charlie Bachtell calls the opening a step toward improving patient access Caveats: no sales, patient volume, or financial impact disclosed. State-licensed medical cannabis; Cresco trades on the CSE and OTCQX. prismmarketview.com/companie…

Bloom Energy ($BE) reported record Q3 revenue of $1.24B, up 138% year over year, as product revenue rose 179% to $1.07B. Operating income reached $225.4M, up $217.6M, and gross margin widened to 33.8%. The company raised its full-year 2026 revenue guidance to $4.4B to $4.6B, about 122% growth at the midpoint, and was added to the S&P 500. prismmarketview.com/companie…

October is National Physical Therapy Month, and this year’s “PT For Future Me” theme is about strength and mobility for life, not just recovery. Five public companies are working on different stages of it: $KIDS: pediatric orthopedics, where lifelong mobility starts $OMDA: a physical therapist-designed exercise plan that helped GLP-1 users lose more weight while gaining muscle $ENOV: braces, recovery tools and joint replacements, from injury to rehab $MYO: the MyoPro powered arm brace, restoring function after stroke and injury $FIGS: outfitting the professionals who make it all work prismmarketview.com/national… #PTForFutureMe

Lucid Diagnostics ($LUCD) began receiving Medicare payments for its EsoGuard esophageal DNA test at the established fee schedule rate of $1,938.01 per test. It also closed a $15M Series C preferred placement with existing shareholders. Payments are coming in for tests run at its Texas lab. Noteholders in the deal said the payments addressed the concerns behind a Medicare-related default provision in its 2029 convertible notes. California lab claims still await a final revised coverage determination, and the Series C converts at $0.3519 with a 20% dividend paid in stock. prismmarketview.com/lucid-di…

$BCTX BriaCell presented an ESMO 2026 poster on a blood-based immune biomarker in metastatic breast cancer: PD-L1 on circulating cancer-associated macrophage-like cells (CAMLs). In a pooled analysis of 111 patients, post-treatment measurements were associated with outcomes, while the pretreatment measurement was not. → At ~37 days: significantly associated with progression-free survival → At ~3 months: significantly associated with both progression-free and overall survival → Pooled patients received different checkpoint inhibitors, some with the Bria-IMT regimen; 60% had triple-negative disease prismmarketview.com/briacell…

$MIRA said oral MIRA-55 delivered pain relief comparable to Celebrex in a 21-day preclinical chronic inflammatory pain study, with no tolerance observed. The data support a planned IND submission. prismmarketview.com/companie…

🔐 BIO-key $BKYI jumped 30.5% to $2.74 and is up again premarket after winning its 7th Gulf government customer in 6 months. A national security institution is deploying PortalGuard, Passkey:YOU and EcoID III. It's leading the PRISM Cybersecurity Index 👇 prismmarketview.com/bio-key-…

$SKYX @skyxplatforms Corp. and its subsidiary Deako announced plans to supply more than 80,000 units of plug-and-play and smart-home technologies for more than 1,000 Maronda Homes residences, with deliveries expected in 2027. → Projects span several states, including Ohio, Georgia, Maryland, and Pennsylvania → Maronda is a privately held builder founded in 1972 with 70,000+ homes built, active in 11 states → Deako’s CEO describes the program as a model for other builder relationships prismmarketview.com/skyx-and…

PRISM M☀️RNING M☀️VERS Premarket Gainers: J-Star Holding Co., Ltd. ($YMAT) - up 62% WISeSat.Space Holdings Corp. ($SAIQ) - up 26% RingCentral, Inc. ($RNG) - up 15% BIO-key International, Inc. ($BKYI) - up 12% Premarket Decliners: Davion Healthcare Plc Ordinary Shares ($DAVI) - down 40% Tantech Holdings Ltd ($TANH) - down 38% Stock prices and percentage changes are as of 8:30 a.m. ET on October 23, 2026, and are subject to change.

$DMAC enrolled the 200th patient in its Phase 2/3 ReMEDy2 acute ischemic stroke trial of DM199, reaching the threshold for a planned interim analysis. Results are expected in Q1 2027. prismmarketview.com/companie…

$BKYI won another Middle East government contract for its PortalGuard passwordless biometric identity platform. It is BIO-key's seventh new customer in the Gulf region in the past six months. prismmarketview.com/companie…

$FUBO signed seven new regional sports network deals for the 2026-27 NBA season, covering teams including the Hawks, Pistons, HEAT, Bucks and Thunder. Its NBA RSN market coverage now tops 75%. prismmarketview.com/companie…

A broad Thursday selloff: 9 of 27 PRISM indexes finished higher, led by fintech at +2.93% while semiconductors lagged at -8.39%. Pet care (+1.69%) and consumer products (+1.23%) also gained, while crypto mining (-7.14%), precious metals (-5.70%) and AI datacenter & infrastructure (-5.08%) trailed. Biggest single-stock moves: $SHFS +122.37%, $BKYI +30.48% and $KRRO +29.71% led the gainers, while $NVEC -33.68%, $HUBC -32.77% and $HAIN -20.70% led the decliners. Full index at prismmarketview.com

$TE received a Commerce Department Section 232 waiver to import up to 1.725GW of solar cells, keeping its G1_Dallas module plant running while it builds a solar cell fab in Texas. prismmarketview.com/companie…

Unusual Machines ($UMAC) received a $16.9M purchase order from Powerus for drone motors, batteries, cameras and video transmitters. The order follows a Powerus order of more than $5M in April and a $30M equity investment Unusual Machines made in Powerus in June. Batteries are a new line after its Upgrade Energy acquisition closed on October 19. Q2 revenue rose 687% to $16.7M, though management said it does not expect Q3 revenue to follow that pattern as it builds capacity for Q4 and 2027. prismmarketview.com/unusual-…